Frontiers in Oncology最新文献

{"title":"Integrated single-cell analysis reveals the regulatory network of disulfidptosis-related lncRNAs in bladder cancer: constructing a prognostic model and predicting treatment response.","authors":"Jiafu Xiao, Wuhao Liu, Jianxin Gong, Weifeng Lai, Neng Luo, Yingfan He, Junrong Zou, Zhihua He","doi":"10.3389/fonc.2025.1527036","DOIUrl":"10.3389/fonc.2025.1527036","url":null,"abstract":"<p><strong>Background: </strong>Disulfidptosis is a newly discovered form of cell death, and long non-coding RNAs (lncRNAs) play a crucial role in tumor cell growth, migration, recurrence, and drug resistance, particularly in bladder cancer (BLCA). This study aims to investigate disulfidptosis-related lncRNAs (DRLs) as potential prognostic markers for BLCA patients.</p><p><strong>Methods: </strong>Utilizing single-cell sequencing data, RNA sequencing data, and corresponding clinical information sourced from the GEO and TCGA databases, this study conducted cell annotation and intercellular communication analyses to identify differentially expressed disulfide death-related genes (DRGs). Subsequently, Pearson correlation and Cox regression analyses were employed to discern DRLs that correlate with overall survival. A prognostic model was constructed through LASSO regression analysis based on DRLs, complemented by multivariate Cox regression analysis. The performance of this model was rigorously evaluated using Kaplan-Meier analysis, receiver operating characteristic (ROC) curves, and area under the ROC curve (AUC). Furthermore, this investigation delved into the potential signaling pathways, immune status, tumor mutation burden (TMB), and responses to anticancer therapies associated with varying prognoses in patients with BLCA.</p><p><strong>Results: </strong>We identified twelve differentially expressed DRGs and elucidated their corresponding intercellular communication relationships. Notably, epithelial cells function as ligands, signaling to other cell types, with the interactions between epithelial cells and both monocytes and endothelial cells exhibiting the strongest connectivity. This study identified six DRLs in BLCA-namely, C1RL-AS1, GK-AS1, AC134349.1, AC104785.1, AC011092.3, and AC009951.6, and constructed a nomogram to improve the predictive accuracy of the model. The DRL features demonstrated significant associations with various clinical variables, diverse immune landscapes, and drug sensitivity profiles in BLCA patients. Furthermore, RT-qPCR validation confirmed the aberrant expression levels of these DRLs in BLCA tissues, affirming the potential of DRL characteristics as prognostic biomarkers.</p><p><strong>Conclusion: </strong>We established a DRLs model that serves as a predictive tool for the prognosis of BLCA patients, as well as for assessing tumor mutation burden, immune cell infiltration, and responses to immunotherapy and targeted therapies. Collectively, this study contributes valuable insights toward advancing precision medicine within the context of BLCA.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1527036"},"PeriodicalIF":3.5,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11919679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy.","authors":"Yingbo Shao, Huijuan Guan, Zhifen Luo, Yang Yu, Yaning He, Qi Chen, Chaojun Liu, Fangyuan Zhu, Hui Liu","doi":"10.3389/fonc.2025.1459444","DOIUrl":"10.3389/fonc.2025.1459444","url":null,"abstract":"<p><strong>Objective: </strong>The present study aimed to evaluate the predictive factors that predict outcomes of HER2-low breast cancer patients who did not achieve pathological complete response(pCR) after neoadjuvant chemotherapy (NAC).</p><p><strong>Methods: </strong>This study included patients with HER2-low breast cancer who received NAC from January 2017 to December 2020. Analysis of the clinicopathological features, NAC response and outcome of the patients were retrospectively analyzed. Univariate and multivariable Cox analysis were used to determine factors that predict outcomes of HER2-low breast cancer patients who did not exhibit pCR.</p><p><strong>Results: </strong>293 Asian patients were included. The proportion of patients with hormone receptor (HR) positive and triple negative breast cancer (TNBC) among HER2-low patients was 75.8% and 24.2%, respectively. The pCR rate of HR positive cases was significantly lower than TNBC (27.5% vs. 53.5%, P=0.000). The patients who obtained pCR after NAC showed better disease-free survival(DFS) (5-year DFS 93.9% vs. 83.1%, p=0.039). For patients not achieving pCR, multivariable analysis showed that Miller/Payne (MP) grading system (hazard ratio: 0.094; 95% CI: 0.037-0.238; p=0.000) and HR status (hazard ratio: 2.561; 95% CI: 1.100-5.966; p=0.029) were significant independent predictors for DFS. Additionally, The MP grading system was also an independent predictor of overall survival (OS) (hazard ratio: 0.071; 95% CI: 0.019-0.260; p=0.000).</p><p><strong>Conclusions: </strong>The results of our study show that pathological assessment following NAC offers valuable insights into the survival outcome of HER2-low breast cancer. According to these findings, responses to NAC should be considered when choosing systemic treatment for patients with HER2-low breast cancer.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1459444"},"PeriodicalIF":3.5,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nomogram combining dual-energy computed tomography features and radiomics for differentiating parotid warthin tumor from pleomorphic adenoma: a retrospective study.","authors":"Zhiwei Gong, Jianying Li, Yilin Han, Shiyu Chen, Lijun Wang","doi":"10.3389/fonc.2025.1505385","DOIUrl":"10.3389/fonc.2025.1505385","url":null,"abstract":"<p><strong>Introduction: </strong>Accurate differentiation between pleomorphic adenomas (PA) and Warthin tumors (WT) in the parotid gland is challenging owing to overlapping imaging features. This study aimed to evaluate a nomogram combining dual-energy computed tomography (DECT) quantitative parameters and radiomics to enhance diagnostic precision.</p><p><strong>Methods: </strong>This retrospective study included 120 patients with pathologically confirmed PA or WT, randomly divided into training and test sets (7:3). DECT features, including tumor CT values from 70 keV virtual monochromatic images (VMIs), iodine concentration (IC), and normalized IC (NIC), were analyzed. Independent predictors were identified via logistic regression. Radiomic features were extracted from segmented regions of interest and filtered using the K-best and least absolute shrinkage and selection operator. Radiomic models based on 70 keV VMIs and material decomposition images were developed using logistic regression (LR), support vector machine (SVM), and random forest (RF). The best-performing radiomics model was combined with independent DECT predictors to construct a model and nomogram. Model performance was assessed using ROC curves, calibration curves, and decision curve analysis (DCA).</p><p><strong>Results: </strong>IC (venous phase), NIC (arterial phase), and NIC (venous phase) were independent DECT predictors. The DECT feature model achieved AUCs of 0.842 and 0.853 in the training and test sets, respectively, outperforming the traditional radiomics model (AUCs 0.836 and 0.834, respectively). The DECT radiomics model using arterial phase water-based images with LR showed improved performance (AUCs 0.883 and 0.925). The combined model demonstrated the highest discrimination power, with AUCs of 0.910 and 0.947. The combined model outperformed the DECT features and conventional radiomics models, with AUCs of 0.910 and 0.947, respectively (P<0.05). While the difference in AUC between the combined model and the DECT radiomics model was not statistically significant (P>0.05), it showed higher specificity, accuracy, and precision. DCA found that the nomogram gave the greatest net therapeutic effect across a broad range of threshold probabilities.</p><p><strong>Discussion: </strong>The nomogram combining DECT features and radiomics offers a promising non-invasive tool for differentiating PA and WT in clinical practice.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1505385"},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11914106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research and progress of microRNA-136 in metastatic tumors.","authors":"Chenwen Wang, Zixiong Chen, Wei Ni, Jiang Wang, Wei Zhou","doi":"10.3389/fonc.2025.1555270","DOIUrl":"10.3389/fonc.2025.1555270","url":null,"abstract":"<p><strong>Background: </strong>MiR-136 is abnormally expressed in many types of metastatic tumors and is closely associated with tumor cell proliferation, apoptosis, invasion, and metastasis, indicating its important role in tumor development and progression. This review summarizes current knowledge regarding miR-136's molecular mechanisms, functional roles, and impact on chemotherapy in different human cancers.</p><p><strong>Methods: </strong>A literature search was conducted in PubMed and Web of Science using \"miR-136\" and \"metastatic tumors\" as English keywords, and in CNKI and Wanfang databases using the same terms in Chinese. Studies related to miR-136 research in metastatic tumors and high-quality evidence from similar studies were included. Meta-analyses, dissertations, conference papers, low-quality articles, unavailable full-text articles, and republished articles were excluded.</p><p><strong>Results: </strong>This review synthesizes the current understanding of miR-136's role in various cancers, including osteosarcoma, gastric cancer, gallbladder cancer, esophageal cancer, prostate cancer, colorectal cancer, breast cancer, glioma, and thyroid cancer. miR-136 acts as a tumor suppressor by targeting various genes, including MTDH, PTEN, MAP2K4, MUC1, LRH-1, MIEN1, RASAL2, CYR61, and KLF7. It influences multiple signaling pathways, including the ERK/mitogen-activated protein kinase, Wnt/β-catenin, Ha-Ras, PI3K/Akt, Aurora-A kinase, nuclear factor-κB, and JNK pathways. Furthermore, miR-136 is involved in chemoresistance by modulating ROCK1, PPP2R2A, and the miR-136-Notch3 signaling axis.</p><p><strong>Conclusions: </strong>MiR-136 demonstrates promising potential as a novel biomarker and therapeutic target in various human cancers. Further research is needed to fully elucidate its complex roles in cancer development, progression, and drug resistance, particularly regarding its potential in immunotherapy.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1555270"},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913677/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric cancer peritoneal metastasis: a bibliometric study from 2000 to 2024 using VOSviewer software.","authors":"Manting Y, Dongfang L","doi":"10.3389/fonc.2025.1489043","DOIUrl":"10.3389/fonc.2025.1489043","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer remains a prevalent malignancy worldwide, with peritoneal metastasis being the predominant form of recurrence and metastasis, which are clear predictors of prognosis. The aim of this comprehensive bibliometric analysis was to assess the current status of the research landscape and to identify impending trends in gastric cancer peritoneal metastasis (GCPM).</p><p><strong>Methods: </strong>Relevant studies of GCPM were retrieved from the Web of Science Core Collection database. Qualified articles were screened based on the inclusion and exclusion criteria for further analysis. The selected publications were then subjected to bibliometric analysis utilizing VOSviewer software.</p><p><strong>Results: </strong>In total, 1,100 publications were included for analysis. The results revealed a consistent upward trend in the number of publications annually from 2000 to 2024, with an anticipated continuation of this growth in future research. The National Cancer Center Japan, emerged as the institution with the most publications and Professor Kodera and <i>Annals of Surgical Oncology</i> were identified as the most influential author and journal, respectively, in the domain of GCPM. In terms of international collaborations, the USA, Japan, and France were the most engaged countries. Yonemura was recognized as the most frequently cited author. Gastrectomy, systemic chemotherapy, and intraperitoneal therapy are the current research hotspots within this domain.</p><p><strong>Conclusion: </strong>Research related to GCPM had rapidly increased over the past two decades. These findings identify the most influential countries, institutions, authors, journals, and academic collaboration networks, while also clarifying hotspots and future trends in GCPM research.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1489043"},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913700/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanisms, assessment, and exercise interventions for skeletal muscle dysfunction post-chemotherapy in breast cancer: from inflammation factors to clinical practice.","authors":"Pei Zhong, Xizhuang Li, Jiehua Li","doi":"10.3389/fonc.2025.1551561","DOIUrl":"10.3389/fonc.2025.1551561","url":null,"abstract":"<p><p>Chemotherapy remains a central component of breast cancer treatment, significantly improving patient survival rates. However, its toxic side effects, along with cancer-related paraneoplastic syndromes, can lead to the loss of skeletal muscle mass and function, impairing physical abilities and increasing the risk of complications during treatment. Chemotherapeutic agents directly impact skeletal muscle cells by promoting protein degradation, inhibiting protein synthesis, and triggering systemic inflammation, all of which contribute to muscle atrophy. Additionally, these drugs can interfere with the proliferation and differentiation of stem cells, such as satellite cells, disrupting muscle regeneration and repair while inducing abnormal differentiation of intermuscular tissue, thereby worsening muscle wasting. These effects not only reduce the effectiveness of chemotherapy but also negatively affect patients' quality of life and disease prognosis. Recent studies have emphasized the role of exercise as an effective non-pharmacological strategy for preventing muscle loss and preserving muscle mass in cancer patients. This review examines the clinical manifestations of muscle dysfunction following breast cancer chemotherapy, the potential mechanisms underlying these changes, and the evidence supporting exercise as a therapeutic approach for improving muscle function.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1551561"},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A CT-based radiomics nomogram for the preoperative prediction of perineural invasion in pancreatic ductal adenocarcinoma.","authors":"Yan Deng, Haopeng Yu, Xiuping Duan, Li Liu, Zixing Huang, Bin Song","doi":"10.3389/fonc.2025.1525835","DOIUrl":"10.3389/fonc.2025.1525835","url":null,"abstract":"<p><strong>Purpose: </strong>To develop a nomogram based on CT radiomics features for preoperative prediction of perineural invasion (PNI) in pancreatic ductal adenocarcinoma (PDAC) patients.</p><p><strong>Methods: </strong>A total of 217 patients with histologically confirmed PDAC were enrolled in this retrospective study. Radiomics features were extracted from the whole tumor. Univariate analysis, least absolute shrinkage and selection operator and logistic regression were applied for feature selection and radiomics model construction. Finally, a nomogram combining the radiomics score (Rad-score) and clinical characteristics was established. Receiver operating characteristic curve analysis, calibration curve analysis and decision curve analysis (DCA) were used to evaluate the predictive performance of the nomogram.</p><p><strong>Results: </strong>According to multivariate analysis, CT features, including the radiologists evaluated PNI status based on CECT (CTPNI) (OR=1.971 [95% CI: 1.165, 3.332], P=0.01), the lymph node status determined on CECT (CTLN) (OR=2.506 [95%: 1.416, 4.333], P=0.001) and the Rad-score (OR=3.666 [95% CI: 2.069, 6.494], P<0.001), were significantly associated with PNI. The area under the receiver operating characteristic curve (AUC) for the nomogram combined with the Rad-score, CTLN and CTPNI achieved favorable discrimination of PNI status, with AUCs of 0.846 and 0.778 in the training and testing cohorts, respectively, which were superior to those of the Rad-score (AUC of 0.720 in the training cohort and 0.640 in the testing cohort) and CTPNI (AUC of 0.610 in the training cohort and 0.675 in the testing cohort). The calibration plot and decision curve showed good results.</p><p><strong>Conclusion: </strong>The CT-based radiomics nomogram has the potential to accurately predict PNI in patients with PDAC.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1525835"},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of disulfidptosis-associated genes in gastric cancer: a comprehensive analysis.","authors":"Jin Tang, Jing Yang, Long-Kuan Yin","doi":"10.3389/fonc.2025.1512394","DOIUrl":"10.3389/fonc.2025.1512394","url":null,"abstract":"<p><strong>Objective: </strong>Disulfidptosis is a newly identified type of nonapoptotic programmed cell death related to mechanisms such as ferroptosis, cuproptosis, pyroptosis, and necrotic apoptosis. This study explores the role of disulfidptosis-related long non-coding RNAs (DRLs) in gastric cancer and their potential as prognostic biomarkers.</p><p><strong>Method: </strong>We developed a prognostic model using DRL scores to classify patients based on disulfidptosis activity. We evaluated these scores for correlations with drug sensitivity, tumor microenvironment (TME) features, tumor mutational burden (TMB), and prognosis. Potential disulfidptosis-related signaling pathways were screened, identifying FRMD6-AS as a promising therapeutic target. FRMD6-AS expression was further validated using real-time fluorescent quantitative PCR (qRT-PCR).</p><p><strong>Results: </strong>The DRL-based prognostic model, established through univariate and multivariate Cox regression and LASSO regression analyses, outperformed traditional models in predicting prognosis. We divided samples into high-risk and low-risk groups based on DRL scores, finding that the low-risk group had a significantly higher survival rate (P < 0.05). A high-precision prediction model incorporating DRL scores, age, sex, grade, and stage showed strong predictive value and consistency with actual outcomes. High DRL scores correlated with higher TME scores and lower TMB. Key signaling axes identified were AC129507.1/(FLNA, TLN1)/FOCAL ADHESION and AC107021.2/MYH10/(TIGHT JUNCTION, VIRAL MYOCARDITIS, REGULATION OF ACTIN CYTOSKELETON). Potentially effective drugs, including BMS-754807, dabrafenib, and JQ1, were identified. FRMD6-AS emerged as a potential target for gastric cancer treatment.</p><p><strong>Conclusions: </strong>This study developed a novel prognostic model for gastric cancer using DRLs, identifying two key signaling axes related to prognosis. JQ1 may be an effective treatment, and FRMD6-AS could be a promising therapeutic target.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1512394"},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of high-grade adenosquamous carcinoma of the breast: case report and literature review.","authors":"Xiaoxiao Xing, Junyi Li, Yangyang Fan, Yun Wang, Yue Wang, Daixiang Liao, Shiyun Zhang","doi":"10.3389/fonc.2025.1548036","DOIUrl":"10.3389/fonc.2025.1548036","url":null,"abstract":"<p><p>High-grade adenosquamous carcinoma (HGASC) is a rare and aggressive subtype of metaplastic breast cancer (MpBC). This article reports a case of HGASC (pT2N0M0 Stage IIA) in a 43-year-old female and reviews the relevant literature, with a specific focus on distinguishing HGASC from other MpBC subtypes, particularly low-grade adenosquamous carcinoma (LGASC). The patient underwent a skin-sparing mastectomy with abdominal rectus myocutaneous flap reconstruction. Histopathology confirmed HGASC with metaplastic features. Postoperative adjuvant chemotherapy with capecitabine was administered. The case highlights the unique clinical, imaging, and pathological characteristics of HGASC, its therapeutic challenges, and the need for individualized treatment strategies. A five-month follow-up showed no signs of recurrence or metastasis.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1548036"},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-omics approach reveals the impact of prognosis model-related genes on the tumor microenvironment in medulloblastoma.","authors":"Dongming Han, Xuan Chen, Xin Jin, Jiankang Li, Dongyang Wang, Ziwei Wang","doi":"10.3389/fonc.2025.1477617","DOIUrl":"10.3389/fonc.2025.1477617","url":null,"abstract":"<p><strong>Background: </strong>The tumor microenvironment (TME) significantly impacts the progression and prognosis of medulloblastoma (MB). This study aimed to develop a TME-associated risk score(TMErisk) model using RNA sequencing data to predict patient outcomes and elucidate biological mechanisms.</p><p><strong>Methods: </strong>RNA sequencing data from 322 Tiantan and 763 GSE85217 MB samples were analyzed. Key gene modules related to immune and stromal components were identified using Weighted Gene Co-expression Network Analysis (WGCNA). Significant genes were screened using LASSO-COX and COX regression models. Single-cell RNA sequencing (scRNA-seq), single-cell ATAC sequencing (scATAC-seq), and spatial RNA analyses validated the findings.</p><p><strong>Results: </strong>Differential expression analysis identified 731 upregulated and 15 downregulated genes in high vs. low immune score MB patients, and 686 upregulated and 43 downregulated genes in high vs. low stromal score patients. Eight key genes (<i>CEBPB</i>, <i>OLFML2B</i>, <i>GGTA1</i>, <i>GZMA</i>, <i>TCIM</i>, <i>OLFML3</i>, <i>NAT1</i>, and <i>CD1C</i>) were included in the TMErisk model, which demonstrated strong prognostic power. High TMErisk scores correlated with poorer survival, distinct immune cell infiltration patterns, and lower tumor cell stemness. Single-cell analyses revealed the expression dynamics of TMErisk genes across cell types, including macrophages, T cells, and NK cells, and identified key regulatory transcription factors. Spatial transcriptomics showed significant clustering of TMErisk genes in tumor regions, highlighting spatial heterogeneity and the formation of immune hubs.</p><p><strong>Conclusions: </strong>The TMErisk model enhances our understanding of the MB tumor microenvironment, serving as a robust prognostic tool and suggesting new avenues for targeted therapy.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1477617"},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}